Antipsychotic polypharmacy in a regional health service: a population-based study by Bernardo Arroyo, Miquel et al.
Bernardo et al. BMC Psychiatry 2012, 12:42
http://www.biomedcentral.com/1471-244X/12/42RESEARCH ARTICLE Open AccessAntipsychotic polypharmacy in a regional health
service: a population-based study
Miguel Bernardo1,2,3,4*, Anna Coma5, Cristina Ibáñez5, Corinne Zara5, Josep Maria Bari1 and Antoni Serrano-Blanco6Abstract
Background: To analyse the extent and profile of outpatient regular dispensation of antipsychotics, both in
combination and monotherapy, in the Barcelona Health Region (Spain), focusing on the use of clozapine and
long-acting injections (LAI).
Methods: Antipsychotic drugs dispensed for people older than 18 and processed by the Catalan Health Service
during 2007 were retrospectively reviewed. First and second generation antipsychotic drugs (FGA and SGA)
from the Anatomical Therapeutic Chemical classification (ATC) code N05A (except lithium) were included. A
patient selection algorithm was designed to identify prescriptions regularly dispensed. Variables included were
age, gender, antipsychotic type, route of administration and number of packages dispensed.
Results: A total of 117,811 patients were given any antipsychotic, of whom 71,004 regularly received such
drugs. Among the latter, 9,855 (13.9%) corresponded to an antipsychotic combination, 47,386 (66.7%) to
monotherapy and 13,763 (19.4%) to unspecified combinations. Of the patients given antipsychotics in
association, 58% were men. Olanzapine (37.1%) and oral risperidone (36.4%) were the most common
dispensations. Analysis of the patients dispensed two antipsychotics (57.8%) revealed 198 different combinations,
the most frequent being the association of FGA and SGA (62.0%). Clozapine was dispensed to 2.3% of patients.
Of those who were receiving antipsychotics in combination, 6.6% were given clozapine, being clozapine plus
amisulpride the most frequent association (22.8%). A total of 3.800 patients (5.4%) were given LAI antipsychotics,
and 2.662 of these (70.1%) were in combination. Risperidone was the most widely used LAI.
Conclusions: The scant evidence available regarding the efficacy of combining different antipsychotics contrasts
with the high number and variety of combinations prescribed to outpatients, as well as with the limited use of
clozapine.
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Antipsychotic drugs are often combined in the clinical
treatment of schizophrenia, despite the lack of a solid
evidence base for this strategy. Indeed, the combination
of antipsychotics has yet to be studied in sufficient de-
tail, although numerous pharmaco-epidemiological stud-
ies describing the phenomenon of antipsychotic
polypharmacy have been conducted internationally.
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reproduction in any medium, provided the ordiffer in terms of methodology, sample size, chronology,
diagnostic criteria, the treatments included and the sal-
vage therapy options [1-8].
The prevalence of antipsychotic polypharmacy in the
USA ranges from 7% to around 50% [9-18], including a
study in child and adolescent population [19], with most
studies reporting rates between 10 and 30%. Similarly,
European data on patients diagnosed with schizophrenia
and being treated in acute psychiatric units reveal that
antipsychotic polypharmacy is a common (if not the
most common) strategy and that it is not reserved for
the most treatment-resistant cases [20,21].
Some authors have also reported a trend towards an
increased use of antipsychotic polypharmacy in theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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based guidelines only recommend concomitant anti-
psychotic treatment after several failed attempts at
monotherapy, including with clozapine [23,24]. Indeed,
the various clinical guidelines with stronger consensus
[25-27] place clear limitations on the use of anti-
psychotic polypharmacy.
It has been suggested that some antipsychotics, both
first (FGA) and second (SGA) generation, are especially
used in polytherapy, whereas others, such as clozapine,
tend to be used as monotherapy [28]. This contrasts
with the large number of published studies on the use of
clozapine in combination as opposed to many of the
combinations that are currently used [29,30]. There is
no specific antipsychotic combination recommended in
the current guidelines [25-27]. In this regard, it would
also seem advisable to analyse the use of long-acting
injections (LAI) of antipsychotics and determine their
profile of use in monotherapy or combination.
In the case of schizophrenia, resistance to treatment
and the unsatisfactory functional outcomes remain a sig-
nificant problem in both the clinical context and in
terms of public health [9,31-33]. To date, clozapine is
the only treatment to have shown significantly better
outcomes than other antipsychotics in partial or non-
responder patients to antipsychotic monotherapy [34-
36]. Furthermore, although numerous maximization
strategies have been tried in randomised controlled stud-
ies, none of them has proved the effectiveness in non-
responders to monotherapy [1-4]. On the other hand, in
some cases antipsychotics could be associated to treat
some symptoms like insomnia, especially clotiapine.
As regards the safety of antipsychotic polypharmacy,
there are data which suggest that its use does not in-
crease side effects or the risk of death by natural causes
[37], although some studies do report a moderate and
additive risk of adverse effects [38].
The present study sought to evaluate the profile of
antipsychotic drugs dispensation in a broad sample over
a one-year period (2007). The aim was to determine the
extent to which these dispensations were in line with
current guidelines and to indicate to policy makers,
managers, clinicians and trainee physicians those areas
which require further research.
Methods
Setting
The study was conducted in the Barcelona Health Re-
gion (BHR), which provides healthcare to 5,105,555
people, making it the largest in Catalonia. Catalonia is
an autonomous region in the northeast of Spain that
covers an area of 32,114 km², its official population in
December 2007 being 7,503,118 inhabitants. Medical
consultations and hospital admissions are fully coveredby the local Catalan Health Service (CatSalut). Prescrip-
tions are free to retired people, while their cost is par-
tially covered for those in employment. In the BHR,
81.0% of people entitled to public healthcare are older
than 18, and of these, 51.6% are women (data from the
local central register for December 2007).Study population
Using the database of official medical prescriptions
(DATAMARTW) processed by the Catalan Health Ser-
vice we selected all out-patient prescriptions for one or
more antipsychotic drugs prescribed by a physician of
CatSalut (independently of the speciality) to a person
over the age of 18 in the BHR, and dispensed during
2007 in a pharmacy in Catalonia. Antipsychotic drugs
prescribed to inpatients at hospital units were not con-
sidered for the purposes of the present study.
The antipsychotic drugs analysed were all those
included (with the exception of lithium) under the code
N05A of the Anatomical Therapeutic Chemical (ATC)
classification system and marketed in Spain. FGAs
(chlorpromazine, clotiapine, fluphenazine, haloperidol,
levomepromazine, perphenazine, periciazine, pimozide,
pipothiazine, sulpiride, tiapride, trifluoperazine and
zuclopenthixol) were distinguished from SGAs (amisul-
pride, aripiprazole, clozapine, olanzapine, quetiapine, ris-
peridone, sertindol and ziprasidone), as well as oral
formulations from long-acting injections (LAI) (fluphe-
nazine LAI, pipothiazine LAI, risperidone oral and LAI,
and zuclopenthixol oral and LAI).Outcome
The aim of the study was to apply a retrospective epi-
demiological analysis to determine the use of anti-
psychotic treatments in combination and as
monotherapy, with particular attention to the use of clo-
zapine and injectable forms.
Three criteria were established to define more specific-
ally the study sample (Figure 1).
Criterion 1: Regularly-dispensed antipsychotic treat-
ment: at least three packages of any antipsychotic dis-
pensed during 2007.
Criterion 2: Monotherapy: for those patients who
were given at least three packages of an antipsychotic a
distinction was made between those prescribed just one
antipsychotic (monotherapy) and those who received
two or more different antipsychotics (antipsychotic
polytherapy).
Criterion 3: Antipsychotic combination treatment:
for those patients receiving antipsychotic polytherapy,
further three filters were applied, based on a review of
the literature [34-36], to define the criterion of anti-
psychotic combination:
Figure 1 Selection algorithm for patients with antipsychotics.
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drugs dispensed in the three months prior to the last
prescription supplied.
2- The filter 1 was not fulfilled, but more than one
package was dispensed in the fourth month prior to
the last prescription supplied.
3- Filters 1 and 2 were not fulfilled, but at least six
packages of each antipsychotic were dispensed
during the year in question.
We assumed that, in general, at least 1 box of medi-
cation covers 1 month of treatment. Further on, we
developed different filters to precise the identification
of patients with antipsychotic combinations. Criterion
1 was used to identify the population with regular dis-
pensation of antipsychotics. Criterion 2 was used to
distinguish patients who received one antipsychotic
from those who received more than one. In any case,
receiving more than one during a year does not mean
that they were used simultaneously; consequently we
applied the 3rd criterion to identify the simultaneousTable 1 Distribution of the study sample according to age an
Age (years) Initial Sample (N= 71,004) Antipsychotic monot
Women N(%) Men N(%) Women N(%)
19-40 6,144 (15.6) 10,808 (34.1) 3,504 (12.6)
41-60 10,242 (26.0) 9,843 (31.1) 6,589 (23.7)
61-80 12,108 (30.8) 7,455 (23.5) 9,277 (33.4)
>80 10,824 (27.5) 3,580 (11.3) 8,379 (30.2)
Total 39,318 (55.4) 31,686 (44.6) 27,749 (58.6)use of antipsychotics and distinguish it from the se-
quential use.
In the 3rd criterion, Filter 2 is used to detect patients
to whom the 1st filter does not apply because multiple
packages have been dispensed simultaneously during the
4th month prior to the last dispensation and conse-
quently the patient has enough medication to cover a
longer period.
The variables recorded referred to demographics (age
and sex) and prescription characteristics (antipsychotic,
route of administration and packages dispensed). No
personal or clinical data of patients have been collected.
This study has been realized with general data obtained
from the pharmacy prescription database, not with indi-
vidual data of subjects. Therefore, no ethical approval
had to be obtained for this study.
Data analysis
A classification algorithm, implemented in Visual Basic
for Applications (VBA), was designed to classify those
patients who met the criteria for receiving antipsychotic
drugs in combination. The results of the tables are
obtained from descriptive statistics. The comparisons
between proportions were made using a Z-test with a
level of significance of 0.05. This statistical analysis was
performed using SPSS v. 16.0.
Results
The initial analysis identified 117,811 patients who had
been dispensed at least one antipsychotic during 2007.
Application of the above mentioned selection criteria
revealed that of these, 71,004 had been regularly dis-
pensed an antipsychotic drug, of whom 47,386 (66.7%)
were given the antipsychotic as monotherapy and 9,855
(13.9%) received more than one antipsychotic combined.
The remaining 13,763 (19.4%) were classified as cases of
unspecified antipsychotic polytherapy as they did not
fulfil criterion number 3 (Figure 1).
Of the 71,004 people who were regularly dispensed
antipsychotic medication, 55.4% were women and 52.2%
were aged between 19 and 60 years (Table 1). Figure 2
shows the sample distribution according to age and sex.
It can be seen that the use of antipsychotics follows ad sex
herapy (n= 47,386) Antipsychotics combined (n = 9,855)
Men N(%) Women N(%) Men N(%)
5,908 (30.1) 1,153 (27.8) 2,517 (44.1)
5,697 (29.0) 1,560 (37.7) 2,297 (40.2)
5,421 (27.6) 900 (21.7) 727 (12.7)
2,611 (13.3) 529 (12.8) 172 (3.0)
19,637 (41.4) 4,142 (42.0) 5,713 (58.0)
Figure 2 Distribution of the 71,004 patients who are given antipsychotics according to age and sex.
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than 54 and women older than 73.
The most widely dispensed drugs were oral risperi-
done (30.3%), olanzapine (25.2%), quetiapine (18.7%) and
haloperidol (15.6%) (Table 2, only shown those drugs
that were used by more than 1% of the total sample).Table 2 Distribution of the population according to the antip
were used in more than 1% of the total sample)
Drug Initial sample (N= 71,004)
People N(%) packages N(%)
Risperidone (oral) 21,537 (30.3) 137,234 (13.8)
Olanzapine 17,895 (25.2) 174,715 (17.6)
Quetiapine 13,292 (18.7) 154,408 (15.5)
Haloperidol 11,053 (15.6) 91,328 (9.2)
Sulpiride 8,274 (11.7) 75,183 (7.6)
Levomepromazine 7,503 (10.6) 86,794 (8.7)
Clothiapine 4,416 (6.2) 33,490 (3.4)
Risperidone (LAI) 3,146 (4.4) 60,524 (6.1)
Amisulpride 2,910 (4.1) 24,957 (2.5)
Aripiprazole 2,855 (4.0) 23,551 (2.4)
Ziprasidone 2,560 (3.6) 19,757 (2.0)
Perphenazine 2,146 (3.0) 15,616 (1.6)
Clozapine 1,615 (2.3) 35,222 (3.5)
Fluphenazine 1,403 (2.0) 6,113 (0.6)
Chlorpromazine 1,209 (1.7) 9,577 (1.0)
Zuclopenthixol (LAI) 1,175 (1.7) 15,406 (1.5)
Trifluoperazine 1,163 (1.6) 11,912 (1.2)
LAI long-acting injection.
(*) Percentage with respect to the total number of patients given antipsychotics inAntipsychotics in combination
Application of the three filter criterion to patients pre-
scribed two or more antipsychotic drugs during the year
in question revealed that 9,855 people were given a com-
bination of antipsychotics. The age and sex distribution
of these patients are shown in Table 1. Men accountedsychotic used (the table only shows those drugs that
People given monotherapy
(N = 47,386)
People given antipsychotics in
combination (N= 9,855)
N(%) N(%)(*)
11,589 (24.5) 3,586 (36.4)
9,619 (20.3) 3,657 (37.1)
5,913 (12.5) 2,883 (29.3)
4,431 (9.4) 2,750 (27.9)
6,933 (14.6) 360 (3.7)
2,435 (5.1) 2,607 (26.5)
628 (1.3) 2,157 (21.9)
654 (1.4) 1,500 (15.2)
655 (1.4) 1,253 (12.7)
664 (1.4) 1,025 (10.4)
721 (1.5) 875 (8.9)
797 (1.7) 623 (6.3)
667 (1.4) 652 (6.6)
212 (0.4) 531 (5.4)
369 (0.8) 387 (3.9)
202 (0.4) 659 (6.7)
280 (0.6) 367 (3.7)
combination (9,855).
Bernardo et al. BMC Psychiatry 2012, 12:42 Page 5 of 9
http://www.biomedcentral.com/1471-244X/12/42for 58.0% of those patients, more frequently in the age
range 19–40. Conversely, in women antipsychotic poly-
pharmacy was more frequent in the age range 41–60.
Overall, however, antipsychotic combination was most
likely prescribed to both men and women aged 19–60
(84.3% and 65.5%, respectively).
The frequency of drug combinations is displayed in
Table 2. The antipsychotics that showed the highest
rates of use in polytherapy were olanzapine (37.1%), oral
risperidone (36.4%), quetiapine (29.3%), haloperidol
(27.9%), levomepromazine (26.5%) and clotiapine
(21.9%).
The combination of two antipsychotics was present in
5,692 patients (57.8%), in a total of 198 different combi-
nations. The most common association was oral risperi-
done plus quetiapine (6.2% of the total number of
associations; Table 3). Combinations of three antipsycho-
tics were present in 2,519 patients (25.6%), with a total
of 526 different combinations. Finally, 1,029 people
(10.4%) received four antipsychotics in combination,
while 615 patients (6.2%) were prescribed five or more.
As regards the total number of combinations accord-
ing to the type of antipsychotic, 6,106 (62.0%) of patients
were dispensed both FGAs and SGAs, while 2,699
(27.4%) received different combinations of SGAs and
1,050 (10.6%) used different combinations of FGAs.
With respect to the route of administration, most
combinations referred to oral antipsychotics (7,193
patients, 73.0%). Table 4 shows the data for combined
oral and LAI treatment, which was present in 2,649
(26.9%) of patients given more than one antipsychotic.Table 3 Combinations of two antipsychotics (the table
only shows those combinations used in more than 2% of
patients)
Antipsychotics Count Percent
Risperidone (oral) +Quetiapine 355 6.2
Risperidone (oral) + Haloperidol 272 4.8
Haloperidol + Levomepromazine 266 4.7
Risperidone (oral) +Olanzapine 237 4.2
Risperidone (oral) + Levomepromazine 232 4.1
Olanzapine +Haloperidol 226 4.0
Olanzapine +Quetiapine 216 3.8
Haloperidol +Quetiapine 204 3.6
Olanzapine + Levomepromazine 189 3.3
Olanzapine + Clothiapine 176 3.1
Risperidone (oral) + Risperidone LAI 162 2.9
Olanzapine +Amisulpride 131 2.3
Olanzapine + Risperidone LAI 123 2.2
Levomepromazine +Quetiapine 118 2.1
Risperidone (oral) + Clothiapine 115 2.0
LAI long-acting injection.The most common combination was a second gener-
ation LAI with an oral SGA (26.2%). Finally, thirteen
people were given a combination of different LAI
antipsychotics.
Antipsychotics in monotherapy
Women accounted for 58.6% of people in antipsychotic
monotherapy. Table 1 shows that men aged 19–40 were
dispensed more antipsychotic drugs than their female
counterparts (30.1% versus 12.6%), whereas women
accounted for a higher proportion of dispensations in
those aged over 80 (30.2% vs. 13.3%).
A total of 81.3% of people were given monotherapy
with one of the following five drugs: oral risperidone
(24.5%), olanzapine (20.3%), sulpiride (14.6%), quetiapine
(12.5%) or haloperidol (9.4%) (Table 2).
Use of clozapine
Clozapine was dispensed to 1,615 patients (2.3%) in the
study sample (N= 71,004), of whom 65.4% were men. Of
those patients on antipsychotic monotherapy, 667 (1.4%)
were given clozapine. In combination therapy, 652
(6.6%) patients were dispensed clozapine, 345 of them in
combinations of three or more antipsychotics.
Table 5 shows the different combinations of two anti-
psychotics that included clozapine (n = 307), the most
frequent being clozapine plus amisulpride (22.8%).
Use of long-acting injections of antipsychotics
Of the study sample, 3,800 (5.4%) of patients were given
a LAI antipsychotic. LAIs were dispensed to 2.4% of
patients who received antipsychotic monotherapy and to
27.0% of those who were given combinations. Risperi-
done was the most commonly used LAI, both in mono-
therapy and in polytherapy (Table 6).
Discussion
This study reveals that antipsychotic polypharmacy was
dispensed to 13.8% of people who were regularly dis-
pensed an antipsychotic drug during 2007. The observed
rate of use of antipsychotic polytherapy is similar to that
reported in previous studies. For example, Kogut et al.
(2005) [39] found, in a population drawn from USTable 4 Patients with antipsychotic combinations
according to type and route of administration
ORAL
FGA SGA FGA and SGA
LAI FGA 236 (8.9%) 420 (15.8%) 505 (19.1%)
SGA 135 (5.1%) 693 (26.2%) 507 (19.1%)
FGA and SGA 6 (0.2%) 63 (2.4%) 84 (3.2%)
LAI long-acting injection.
FGA first generation antipsychotic.
SGA second generation antipsychotic.
Table 5 Patients with two antipsychotics combined
including clozapine
Antipsychotics Count Percent
Clozapine Amisulpride 70 22.8
Clozapine Haloperidol 35 11.4
Clozapine Risperidone (oral) 31 10.1
Clozapine Aripiprazole 29 9.4
Clozapine Ziprasidone 27 8.8
Clozapine Quetiapine 20 6.5
Clozapine Levomepromazine 19 6.2
Clozapine Zuclopenthixol (LAI) 14 4.6
Clozapine Clothiapine 13 4.2
Clozapine Olanzapine 13 4.2
Clozapine Perphenazine 11 3.6
Clozapine Risperidone (LAI) 11 3.6
Clozapine Sulpiride 4 1.3
Clozapine Pimozide 3 1.0
Clozapine Chlorpromazine 2 0.7
Clozapine Pipothiazine 2 0.7
Clozapine Fluphenazine 1 0.3
Clozapine Trifluoperazine 1 0.3
Clozapine Zuclopenthixol (oral) 1 0.3
Total 307 100
LAI long-acting injection.
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polypharmacy. The criteria used by Kogut et al. to clas-
sify a patient as an antipsychotic user and to define anti-
psychotic polypharmacy were similar to those applied
here. Also, other studies reported a prevalence of poly-
pharmacy of 15.6% [17]. However, some studies have
used an antipsychotic polypharmacy criterion that, in
our view, is too broad (two or more antipsychotics used
simultaneously) [16,40], thus yielding notably higher pre-
scription rates (41% and 50%). Given that the central
aim of the present study was to analyse the regular use
of antipsychotic combinations, three restrictive criteriaTable 6 Type of antipsychotic combinations in patients with
Monotherapy
(N= 47,386)
Combination with on
FGA
Risperidone LAI 654 (1.4%) 95 (1.6%)
Fluphenazine 212 (0.4%) 49 (0.8%)
Zuclopenthixol LAI 202 (0.4%) 46 (0.8%)
Pipothiazine 70 (0.1%) 27 (0.4%)
TOTAL LAI 1,138 (2.4%) 217 (3.8%)
LAI long-acting injection.
FGA first generation antipsychotic.
SGA second generation antipsychotic.were applied to avoid including combinations when the
patient was switching between antipsychotic treatments.
Yang et al. (2008) [41], applying shorter time criteria (at
least six weeks of simultaneous use and twelve weeks if
one of the drugs used was clozapine), reported an
increased rate of use from 1.9% in 1997 to 5.5% in 2000.
Another study of community-treated patients with
schizophrenia found that 42.5% were given more than
one antipsychotic [42], although this variation may be
due to differences in the methods used.
Overall, men were more likely to be given an anti-
psychotic when they were aged under 60. The profile of
use of drug combinations in women extends beyond
80 years of age. The present findings are consistent with
previous reports showing that antipsychotic polyphar-
macy is more widely used in men [39,42], possibly due
to the increased severity of treatment-resistant schizo-
phrenia among males [43].
The 57.8% of all combinations involved two anti-
psychotic drugs, most commonly oral risperidone plus
quetiapine. Of those treated with combinations, 25.6%
were given three antipsychotics. The 16.6% of patients
were dispensed four or more antipsychotics.
One notable pattern of use identified in this study
involved the combination of a FGA and a SGA (62.0%),
which contrasts with previous reports in the literature
(79.3% used two non-conventional antipsychotics or
SGA) [39].
Clozapine was given to 1,615 (2.3%) patients, 41.3% of
these in monotherapy and as part of antipsychotic poly-
therapy in 58.7%. The most common combination was
clozapine plus amisulpride. The rate of clozapine use
found in the present study is lower than that previously
reported. For example, Pickar et al. (2008) [42] stated
that 18% of their patients were given clozapine, although
this higher rate may be related to the fact that they only
included patients with severe schizophrenia treated in
the community.
LAI formulations are frequently used to ensure treat-
ment adherence that was not achieved with the oral for-
mulation. Consequently, oral and LAI risperidoneLAI antipsychotics
e oral antipsychotics (N= 5,692) Combination with ≥2
antipsychotics(N = 4,163)SGA
445 (7.8%) 948 (22.7%)
74 (1.3%) 405 (9.7%)
178 (3.1%) 424 (10.1%)
49 (0.8%) 111 (2.6%)
746 (13.1%) 1,699 (40.8%)
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from oral to LAI formulation, but not when used as a
combination. As the criteria used to identify anti-
psychotic combinations tried to avoid the switching peri-
ods, the 162 patients identified in our study would
correspond to combinations that are difficult to explain.
Clinicians continue to face numerous challenges in the
treatment of schizophrenia, since ‘antipsychotic’ drugs
do not function as ‘anti-schizophrenic’ drugs and do not
act on comorbid conditions such as anxiety, or asso-
ciated problems such as aggressiveness or suicidal risk.
This leads to the use of multiple drug therapies, espe-
cially for reducing the mean length of hospital admis-
sions. In our view, clinicians often base their arguments
on the pharmacodynamic, pharmacokinetic or tolerance
characteristics of different drugs, although psychiatrists
generally consider antipsychotic polypharmacy as a
largely ineffective strategy for patients who present re-
sistant positive symptoms of psychosis [44].
Initiatives developed in this regard include the soft-
ware package Psychiatric Clinical Knowledge Enhance-
ment System (PSYCKES) [45], which enables clinicians
to easily track the medication taken by their patients, as
well as that prescribed by their peers, increasing the ro-
bustness of the decision-making process. A similar strat-
egy was described in the Developing Evidence-Based
Implementation Trial (DEBIT) [46], based on a multi-
faceted intervention involving an educational/cognitive-
behaviour therapy workbook, an educational visit to
consultants and a reminder system on medication
charts. Both strategies led to reductions in the costs
resulting from polypharmacy, crucial when prescribing
antipsychotic combinations.
Limitations
The first limitation concerns the lack of diagnoses asso-
ciated with the database used. Although antipsychotics
are the drugs of choice for schizophrenia they may also
be indicated in bipolar disorder, behavioural disorders
associated with cognitive deterioration, and in other psy-
chiatric or neurological disorders. It is important to clar-
ify that the objective of the study is to describe the use
of antipsychotic combination, independent of the diag-
noses. Further research could be conducted linking our
database with others containing diagnoses (since ours
had no diagnoses). This could help to analyse the differ-
ences and preferences on the use of antipsychotic com-
binations depending on the diagnoses. Moreover, the
lower rate of clozapine use found in the present study,
compared with that reported in other studies, doesn’t
necessarily mean a lower rate of use for schizophrenia,
as this study includes patients with different possible
diagnoses. The fact of not knowing the diagnosis makes
it impossible to analyse the use of antipsychoticcombinations depending on the severity of the illness.
Also it’s impossible to know if there is a great potential
for off label use in our sample.
The second limitation is that the analysis did not con-
sider antipsychotic drugs prescribed neither in private
practice nor to inpatients. The data correspond to drugs
dispensed by pharmacies when presented with a pre-
scription by a doctor from the Catalan National Health
Service, which includes mental health centres, out-
patient and emergency departments, community re-
habilitation centres and other out-patient facilities. These
account for the majority of prescriptions issued, since in
our healthcare context the cost of these drugs makes it
unlikely that they would be widely prescribed on a pri-
vate basis. All the population from Catalonia is insured
by the Catalan Health Service and pharmacy products
are covered for the 98% of the patients insured. However,
it is not possible to know precisely if we have considered
all the antipsychotics used, due to the fact that part of
the population may also have a private insurance and
thus pay themselves for the treatment. Interventions that
aim to promote the rational use of antipsychotics should
also include prescription rates upon hospital discharge or
in emergency units, since these can influence the main-
tenance treatment subsequently received by a patient.
The third limitation relays on the nature of our data.
We used an administrative database of prescriptions
processed by the National Health Service, and the meas-
ure taken into account was the number of packages dis-
pensed to a patient upon presenting a prescription in a
pharmacy. Therefore, the analysis concerned drugs dis-
pensed rather than the prescription itself. It was also not
possible to study the prescribed dose. Evaluating the
treatment and its results, although interesting, was not
an aim of our study. The prescribed dose could also
affect the number of packages dispensed in a period of
time, which would interfere with our study because the
criteria we used to establish the study population were
based on the number of packages dispensed. Similar
studies using databases of medical records could com-
plement the results of the present study.
Moreover, the criteria established to define the study
sample tried to identify the simultaneous use of anti-
psychotic and distinguish it from the sequential use. The
only way to accurately identify antipsychotic combin-
ation would have been through the prescription date but
that was not available in our administrative database.
Consequently, the filters used to identify antipsychotic
combination were restrictive and a large proportion of
patients were excluded from this definition and labelled
as unspecified polytherapy.
The fourth limitation concerns the safety of using
combinations of antipsychotics. As the data analysed do
not include morbidity rates they are unable to shed any
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ther research that takes an approach like the STAR*D
[47] study with antidepressants, analysing different strat-
egies of sequenced treatment with antipsychotics.
Conclusions
Although antipsychotic polypharmacy is widely used in
our healthcare setting, it appears not to follow the avail-
able clinical practice guidelines indicating the use of
using antipsychotic monotherapy, not in combination.
Although there is no evidence of any effective anti-
psychotic combination, it could be very interesting to
analyse in depth which are the most appropriate anti-
psychotic combinations used in the population of Cata-
lonia. This would guide psychiatrists and general
practitioners in their everyday clinical practice. Develop-
ing strategies for enhancing the use of recommendations
in clinical practice will render the work clinicians more
efficient and understandable in the eyes of policy
makers, and vice-versa.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All the authors of the article have participated in: 1) making substantial
contributions to conception and design, or acquisition of data, or analysis
and interpretation of data; 2) writing the drafts of the manuscript or revising
them critically for important intellectual content; and 3) giving final approval
of the version to be published.
Acknowledgements
The authors thank the Government of Catalonia, Comissionat per Universitats
I Recerca del Departament d’Innovació, Universitats I Empresa (DIUE)
2009SGR1295 and Mike Maudsley at the Language Advisory Service,
University of Barcelona, Spain, for manuscript translation. Also, the authors
thank to Cristina Oliveira, MD, PhD, Alicia Valiente, MD, and Clemente García,
MD, PhD, the support in this project.
Author details
1Schizophrenia Clinic Program, Department of Psychiatry, Neuroscience
Institute, Hospital Clinic de Barcelona, Barcelona, Spain. 2Department of
Psychiatry and Clinical Psychobiology, Health Sciences Division, University of
Barcelona, Barcelona, Spain. 3Institut d’Investigacions Biomèdiques August Pi
i Sunyer (IDIBAPS), Barcelona, Spain. 4Centro de Investigación Biomédica en
Red de Salud Mental (CIBERSAM), Barcelona, Spain. 5Pharmacy Direction.
Catalan Health Service, Barcelona, Spain. 6Parc Sanitari Sant Joan de Déu,
Servicios de Salud Mental y Fundación Sant Joan de Déu, Red de
Investigación en Actividades Preventivas y Promoción de la Salud (RedIAPP),
Barcelona, Spain.
Received: 9 November 2010 Accepted: 17 February 2012
Published: 15 May 2012
References
1. Megna JL, Kunwar AR, Mahlotra K, Sauro MD, Devitt PJ, Rashid A: A study of
polypharmacy with second generation antipsychotics in patients with
severe and persistent mental illness. J Psychiatr Pract 2007, 13(2):129–137.
2. Hazra M, Mamo DC, Remington G: Adjunctive versus monotherapeutic
treatment for schizophrenia: addressing antipsychotic side effects. Am J
Psychiatry 2008, 165(3):396–397. author reply 397–398.
3. Gilmer TP, Dolder CR, Folsom DP, Mastin W, Jeste DV: Antipsychotic
polypharmacy trends among Medicaid beneficiaries with schizophrenia
in San Diego County, 1999–2004. Psychiatr Serv 2007, 58(7):1007–1010.4. Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson M: Adding or switching
antipsychotic medications in treatment-refractory schizophrenia.
Psychiatr Serv 2007, 58(7):983–990.
5. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS: Clinical and social
determinants of antipsychotic polypharmacy for Chinese patients with
schizophrenia. Pharmacopsychiatry 2007, 40(2):47–52.
6. Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC: Long-term
antipsychotic polypharmacy in the VA health system: patient
characteristics and treatment patterns. Psychiatr Serv 2007, 58(4):489–495.
7. Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ: Prevalence,
utilization patterns, and predictors of antipsychotic polypharmacy:
experience in a multistate Medicaid population, 1998–2003. Clin Ther
2007, 29(1):183–195.
8. Broekema WJ, de Groot IW, van Harten PN: Simultaneous prescribing of
atypical antipsychotics, conventional antipsychotics and anticholinergics-
a European study. Pharm World Sci 2007, 29(3):126–130.
9. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic
drugs in patients with chronic schizophrenia. N Engl J Med 2005,
353(12):1209–1223.
10. Correll CU, Frederickson AM, Kane JM, Manu P: Does antipsychotic
polypharmacy increase the risk for metabolic syndrome? Schizophr Res
2007, 89(1–3):91–100.
11. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC: Prevalence, trends,
and factors associated with antipsychotic polypharmacy among
Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry
2004, 65(10):1377–1388.
12. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J: Antipsychotic
monotherapy and polypharmacy in the naturalistic treatment of
schizophrenia with atypical antipsychotics. BMC Psychiatry 2005, 5:26.
13. Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC: Long-term
combination antipsychotic treatment in VA patients with schizophrenia.
Schizophr Res 2006, 84(1):90–99.
14. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N:
Combination antipsychotic therapy in clinical practice. Psychiatr Serv
2003, 54(1):55–59.
15. Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH,
Johnson JL, Barr AM: Persistent antipsychotic polypharmacy and
excessive dosing in the community psychiatric treatment setting: a
review of medication profiles in 435 Canadian outpatients. J Clin
Psychiatry 2010, 71(5):566–573.
16. Karagianis J, Williams R, Davis L, et al: Antipsychotic switching: results from
a one-year prospective, observational study of patients with
schizophrenia. Curr Med Res Opin 2009, 25(9):2121–2132.
17. Smith G, Malla A, Williams R, Kopala L, Love L, Balshaw R: The Canadian
national outcomes measurement study in Schizophrenia: overview of
the patient sample and methodology. Acta Psychiatr Scand Suppl 2006,
430:4–11.
18. Ranceva N, Ashraf W, Odelola D: Antipsychotic polypharmacy in
outpatients at Birch Hill Hospital: incidence and adherence to guidelines.
J Clin Pharmacol 2010, 50(6):699–704.
19. Mojtabai R, Olfson M: National trends in psychotropic medication
polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010,
67(1):26–36.
20. Lerma-Carrillo I, de Pablo Bruhlmann S, del Pozo ML, Pascual-Pinazo F,
Molina JD, Baca-Garcia E: Antipsychotic polypharmacy in patients with
schizophrenia in a brief hospitalization unit. Clin Neuropharmacol 2008,
31(6):319–332.
21. Divac N, Jasovic-Gasic M, Samardzic R, Lackovic M, Prostran M:
Antipsychotic polypharmacy at the University Psychiatric Hospital in
Serbia. Pharmacoepidemiol Drug Saf 2007, 16(11):1250–1251.
22. Clark RE, Bartels SJ, Mellman TA, Peacock WJ: Recent trends in
antipsychotic combination therapy of schizophrenia and schizoaffective
disorder: implications for state mental health policy. Schizophr Bull 2002,
28(1):75–84.
23. Miller AL, Hall CS, Buchanan RW, et al: The Texas Medication Algorithm
Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin
Psychiatry 2004, 65(4):500–508.
24. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO,
Kreyenbuhl J: Practice guideline for the treatment of patients with
schizophrenia, second edition. Am J Psychiatry 2004,
161(2 Suppl):1–56.
Bernardo et al. BMC Psychiatry 2012, 12:42 Page 9 of 9
http://www.biomedcentral.com/1471-244X/12/4225. Ministerio dSyC: Guía de práctica clínica para la atención al paciente con
esquizofrenia. Available at: http://www.gencat.cat/salut/depsan/units/
aatrm/pdf/gpc_esquizofrenia-aatrm09.pdf.
26. American PA: Guideline for the treatment of patients with schizophrenia
[monografía en Internet]. Available at: http://www.pbhcare.org/pubdocs/
upload/documents/APA%20Schzophrenia%20Guidelines%202004.pdf.
27. Texas MAPT: Algorithm for the Treatment of Schizophrenia.
28. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S: Antipsychotic
combinations vs monotherapy in schizophrenia: a meta-analysis of
randomized controlled trials. Schizophr Bull 2009, 35(2):443–457.
29. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A: Does the addition of a
second antipsychotic drug improve clozapine treatment? Schizophr Bull
2009, 35(2):458–468.
30. Cipriani A, Boso M, Barbui C: Clozapine combined with different
antipsychotic drugs for treatment resistant schizophrenia. Cochrane
Database Syst Rev 2009, (3):CD006324.
31. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred
years of schizophrenia: a meta-analysis of the outcome literature. Am J
Psychiatry 1994, 151(10):1409–1416.
32. Jones PB, Barnes TR, Davies L, et al: Randomized controlled trial of the
effect on Quality of Life of second- vs first-generation antipsychotic
drugs in schizophrenia: cost utility of the latest antipsychotic drugs in
schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006,
63(10):1079–1087.
33. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM:
Symptomatic and functional recovery from a first episode of
schizophrenia or schizoaffective disorder. Am J Psychiatry 2004,
161(3):473–479.
34. Kane JM, Honigfeld G, Singer J, Meltzer H: Clozapine in treatment-resistant
schizophrenics. Psychopharmacol Bull 1988, 24(1):62–67.
35. McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine
versus olanzapine, quetiapine, and risperidone in patients with chronic
schizophrenia who did not respond to prior atypical antipsychotic
treatment. Am J Psychiatry 2006, 163(4):600–610.
36. Lewis SW, Barnes TR, Davies L, et al: Randomized controlled trial of effect
of prescription of clozapine versus other second-generation
antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006,
32(4):715–723.
37. Baandrup L, Gasse C, Jensen VD, et al: Antipsychotic polypharmacy and
risk of death from natural causes in patients with schizophrenia: a
population-based nested case–control study. J Clin Psychiatry 2009,
71(2):103–108.
38. Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E: Benefits and risks of
antipsychotic polypharmacy: an evidence-based review of the literature.
Drug Saf 2008, 31(1):7–20.
39. Kogut SJ, Yam F, Dufresne R: Prescribing of antipsychotic medication in a
medicaid population: use of polytherapy and off-label dosages. J Manag
Care Pharm 2005, 11(1):17–24.
40. Schumacher JE, Makela EH, Griffin HR: Multiple antipsychotic medication
prescribing patterns. Ann Pharmacother 2003, 37(7–8):951–955.
41. Yang M, Barner JC, Lawson KA, Rascati KL, Wilson JP, Crismon ML, Worchel J,
Mascarenas CA: Antipsychotic medication utilization trends among Texas
veterans: 1997–2002. Ann Pharmacother 2008, 42(9):1229–1238.
42. Pickar D, Vinik J, Bartko JJ: Pharmacotherapy of schizophrenic patients:
preponderance of off-label drug use. PLoS One 2008, 3(9):e3150.
43. Usall J, Suarez D, Haro JM: Gender differences in response to
antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res
2007, 153(3):225–231.
44. Pandurangi AK, Dalkilic A: Polypharmacy with second-generation
antipsychotics: a review of evidence. J Psychiatr Pract 2008, 14(6):345–367.
45. Uttaro T, Finnerty M, White T, Gaylor R, Shindelman L: Reduction of
concurrent antipsychotic prescribing practices through the use of
PSYCKES. Adm Policy Ment Health 2007, 34(1):57–61.46. Thompson A, Sullivan SA, Barley M, Strange SO, Moore L, Rogers P, Sipos A,
Harrison G: The DEBIT trial: an intervention to reduce antipsychotic
polypharmacy prescribing in adult psychiatry wards - a cluster
randomized controlled trial. Psychol Med 2008, 38(5):705–715.
47. Insel TR: Beyond efficacy: the STAR*D trial. Am J Psychiatry 2006,
163(1):5–7.
doi:10.1186/1471-244X-12-42
Cite this article as: Bernardo et al.: Antipsychotic polypharmacy in a
regional health service: a population-based study. BMC Psychiatry 2012
12:42.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
